ClinicalTrials.gg
CompletedNCT03922308SOAR-HIUpdated Dec 1, 2022Results posted

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

A Phase 2 interventional study of Placebo and SHP655 in Acquired Thrombotic Thrombocytopenic Purpura (aTTP), sponsored by Shire. Completed at 24 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-01.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda — 3 open to participants now, 4 under way, 1 of them phase 3. Purpura, Thrombotic Thrombocytopenic · Takeda.

Started
2019
the only one that year
Phase 2
2 of 10
none open now
Registered
4th of 10
by date

Among the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda, this one is the only one that started in 2019, is one of 2 in phase 2, and was the 4th registered.

Purpura, Thrombotic Thrombocytopenic

67 studies on the registry are indexed under Purpura, Thrombotic Thrombocytopenic; 18 are open to participants now.

Browse Purpura, Thrombotic Thrombocytopenic studies →

Open to participants now

3 of the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 16 Purpura, Thrombotic Thrombocytopenic studies recruiting now, 12 (75%) set no upper age limit and 1 (6%) stops at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to standard of care (SoC) treatment of acquired thrombotic thrombocytopenic purpura (aTTP) participants.

03

Conditions studied

  • Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant or legally authorized representative voluntarily signs . For participants unable to provide consent, a fully recognized medical proxy may be used according to local laws.
  • Participant is 18 to 75 years old at the time of screening.
  • Participant has been diagnosed with primary or secondary acquired thrombotic thrombocytopenic purpura (aTTP) based on the following criteria:

    a) Thrombocytopenia [drop in count >=50% or platelet count \<100,000/microlitre (μL)] i) No more than 3 participants per arm may be enrolled with a screening platelet count >= 50,000/μL.

    b) Microangiopathic hemolytic anemia [elevation of lactate dehydrogenase (LDH) >2-fold or by presence or increase of schistocytes in peripheral blood smear].

  • Willingness to fully comply with study procedures and requirements, and intention to initiate plasma exchange (PEX). Participants may be provisionally entered into the trial and undergo randomization pending the results of the ADAMTS-13 activity, anti-ADAMTS-13 antibody, and genetic testing for congenital thrombotic thrombocytopenic purpura (cTTP).
  • If female of , participant presents with a negative pregnancy test and agrees to employ adequate measures for the duration of the study. Sexually active males must use an accepted and effective method of contraception during the treatment and until a minimum of 16 days after the last dose administered.

Exclusion criteria

Exclusion Criteria:

  • Participant has been diagnosed with congenital TTP.
  • Participant has plasma ADAMTS-13 activity > 10% of normal at the central lab; if screening samples are not taken until after the first PEX, ADAMTS-13 activity from the local lab is permitted to determine eligibility.
  • Participant has been diagnosed with another cause of thrombotic microangiopathy (TMA) including: DIC, disseminated , malignant hypertension, hematopoietic stem cell transplantation, shiga toxin related and atypical HUS, drug toxicity (e.g. gemcitabine, mitomycin C, clopidogrel) and pregnancy-related thrombocytopenia syndromes (e.g. HELLP, eclampsia).
  • Participant has been exposed to another IP within 30 days prior to enrollment or is scheduled to participate in another clinical study involving IP or device during the course of the study.
  • Participant has received caplacizumab within 1 month prior to study enrollment.
  • Participant is positive (HIV+) with unstable disease or \<=200 cells/mm\^3 within 3 months screening.
  • Participants with conditions of severe immunodeficiency.
  • Participant has had a previous aTTP event in the past 30 days.
  • Participant has another underlying progressive fatal disease and/or of less than 3 months.
  • Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures
  • Participant suffers from a mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude. However, a fully recognized medical proxy will be permitted to provide consent.
  • If female, participant is pregnant or lactating.
  • Participant is a family member or employee of the Sponsor or investigator.
  • Any to PEX, methylprednisolone and/or rituximab as per prescribing information.
  • Known life-threatening reaction, including anaphylaxis, to the parent molecule ADAMTS-13, hamster protein, or other constituents of SHP655.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Placebo comparator
    Standard of Care (SoC) + Placebo

    Participants received SoC daily PEX followed by placebo immediately and 12 +/- 1 hours after completion of PEX until remission was achieved (up to approximately 6 months).

    Other: Placebo · Other: Standard of Care

  • Experimental
    SoC + SHP655 + Placebo

    Participants received SoC daily PEX and SHP655 40 +/- 4 international units per kilogram (IU/kg), IV injection, QD, immediately after PEX and placebo 12 +/- 1 hours after completion of PEX until remission was achieved (up to approximately 6 months).

    Other: Placebo · Drug: SHP655 · Other: Standard of Care

  • Experimental
    SoC + SHP655

    Participants received SoC daily PEX and SHP655 40 +/- 4 IU/kg, IV injection, BID, immediately after PEX and 12 +/- 1 hours after completion of PEX until remission was achieved (up to approximately 6 months).

    Drug: SHP655 · Other: Standard of Care

Interventions

  • OtherPlacebo

    Participants will receive injection of placebo matched to SHP655.

  • DrugSHP655

    Participants will receive injection of SHP655.

    Also known as: rADAMTS-13

  • OtherStandard of Care

    Participants will receive PEX as Standard of Care (SOC).

    Also known as: PEX

06

What researchers measure

Primary outcomes

  1. ADAMTS-13 Activity Levels

    ADAMTS-13 Activity Levels was assessed by fluorescence resonance energy transfer (FRETS) ADAMTS13 activity, with or without SHP655 Supplementation. Schedule A (Days 1, 2, 3, 4, 6, 8, 11, and every 3 days thereafter) or Schedule B (Days 1, 2, 3, 5, 7, 9, 12, and every 3 days thereafter). Data is reported for multiple timepoints as Within 15 minutes pre-PEX and post-PEX; Within 15 minutes, 0.5-3 hours, 4-6 hours post end of investigational product (IP) infusion 1; Within 15 minutes, 0.5-3 hours post end IP infusion 2; 30 minutes pre-IP infusion 2 of Schedule A and Schedule B (up to Day 11 or 12).

    Time frame: Up to Days 11 or 12

  2. Platelet Count

    The platelet counts are reported in units of 10\^9 per liter blood.

    Time frame: Baseline and end of study (EOS) (up to approximately 15 months)

  3. Lactate Dehydrogenase (LDH) Levels

    The lactate dehydrogenase levels are reported.

    Time frame: Baseline and EOS (up to approximately 15 months)

Secondary outcomes

  1. Dose(s) of SHP655 Needed to Achieve and Maintain Adequate Plasma Levels of rADAMTS-13

    Dose(s) of SHP655 needed to achieve and maintain adequate plasma levels of rADAMTS-13 in order to support induction of remission and to reduce the number of PEX procedures needed for the treatment of acute aTTP episodes was assessed.

    Time frame: From start of study drug administration up to 13 weeks (following remission up to 6 months)

  2. PK/PD Temporal Relationship of Safety and Efficacy Parameter as a Function of ADAMTS-13 Activity

    Parameters included platelet and LDH counts.

    Time frame: Up to 6 months

  3. Number of Participants With ADAMTS-13 Binding Antibodies Per Titer

    Antibody titer indicates the level of the antibodies in a blood sample, defined as the greatest dilution (or lowest concentration) of the blood sample at which an antibody assay (such as ELISA for e.g.), still produces a detectable positive result. Data is presented per titer for ADA positive participants only.

    Time frame: Baseline and EOS (up to approximately 15 months)

  4. Inhibitory Autoantibodies (Nab) Titer Levels

    NAb titers were summarized (median, minimum and maximum) at baseline and EOS per treatment arms, in those subjects with NAb positive results (NAb positive is defined as titer value \>=0.6 BU/mL).

    Time frame: Baseline and EOS (up to approximately 15 months)

  5. ADAMTS-13 Activity Levels in Participants Receiving Additional SHP655 for up to 30 Days After Resolution by Using FRETS

    ADAMTS-13 activity levels in participants receiving additional SHP655 for up to 30 days after the resolution of the thrombotic thrombocytopenic purpura (TTP) episode were assessed. Resolution was defined as a normal platelet count and LDH \<2 ULN for at least 48 hours following initial normalization of platelet count (acute episode period).

    Time frame: At Days 3, 7, 10, 21, 28, 42, 56 and 84

  6. Relationship Between ADAMTS-13 Activity and End-organ Disease Status

    End-organ disease status were evaluated for renal, cardiac and neurological diseases.

    Time frame: Up to 6 months

  7. Predose Concentration (Cpre) to Maximum Plasma Concentration (Cmax) Ratio

    Time frame: Pre-PEX and post-PEX at multiple timepoints at Days 1, 2, 3, 4 or 5, 6 or 7, 8 or 9, and 11 or 12

  8. AUC Overall: Area Under the Plasma Concentration Time Curve ADAMTS13 Activity by Using FRETS

    Time frame: Within 15 min pre-PEX and at multiple timepoints Post PEX at Days 1, 2, 3, 4 or 5 and 6 or 7

  9. Systemic and Antibody Induced Clearance

    Time frame: 15 minutes pre-PEX,15 minutes post-PEX,15 minutes, 0.5-3 hours, 4-6 hours post end of IP infusion 1,30 minutes pre-IP infusion 2,15 minutes, 0.5-3 hours post-IP infusion 2 of Schedule A or Schedule B (up to 6 months)

  10. Cmax: Maximum ADAMTS-13 Activity Between PEX or SHP655 Infusions by Using FRETS

    Time frame: Pre-PEX and post-PEX at multiple timepoints at Days 1, 2, 3, 4 or 5, 6 or 7, 8 or 9, and 11 or 12

  11. Trough Levels of ADAMTS-13 Prior PEX ADAMTS13 Activity by Using FRETS

    Time frame: Within 15 min pre-PEX and at multiple timepoints Post PEX at Days 2, 3, 4 or 5 and 6 or 7

  12. Percentage of Participants With ADAMTS-13 Activity Trough Levels >10%

    Time frame: Pre-dose at Days 2, 3 4 or 5, 6 or 7, 8 or 9, and 11 or 12

  13. Number of Participants Who Achieved Remission Following Normalization of Platelet Count

    Remission was defined as the time taken to achieve platelet count ≥150,000/μL, which was confirmed by a second normal platelet count ≥150,000/μL and LDH \<2 ULN 48 hours following initial normalization.

    Time frame: From the start of study drug administration up to 6 months post remission

  14. Percentage of Participants Achieving Remission

    Remission was defined as a normal platelet count and LDH \<2 upper limit of normal (ULN) for at least 48 hours following initial normalization of platelet count (acute episode period). Normalization of platelet count was defined ≥150,000/μL, which was confirmed by a second normal platelet count ≥150,000/μL and LDH \<2 ULN.

    Time frame: From the start of study drug administration up to 6 months post remission

  15. Time to First Exacerbation

    Exacerbation was defined as recurrent thrombocytopenia following a response and requiring a reinitiation of daily plasma exchange treatment after ≥1 day but ≤30 days of no plasma exchange treatment. Data is reported based on Kaplan-Meier estimates. Data was reported for time to first exacerbation in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).

    Time frame: From start of study drug administration up to EOS (up to approximately 15 months)

  16. Time to Relapse

    Relapse was determined by platelet count or the occurrence after remission of a major clinical event (e.g., Myocardial Infraction (MI), stroke, death) deemed by the investigator to be related to aTTP. Data was reported for time to relapse in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).

    Time frame: From start of study drug administration up to EOS (up to approximately 15 months)

  17. Percentage of Participants With Exacerbation

    Exacerbation was determined by platelet count or the occurrence after remission of a major clinical event (e.g., myocardial infarction (MI), stroke, death) deemed by the investigator to be related to aTTP. Data was reported for percentage of participants with exacerbation in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).

    Time frame: From start of study drug administration up to EOS (up to approximately 15 months)

  18. Percentage of Participants With Relapse

    Relapse was determined by platelet count or the occurrence after remission of a major clinical event (e.g., Myocardial Infraction (MI), stroke, death) deemed by the investigator to be related to aTTP. Data was reported for percentage of participants with exacerbation in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).

    Time frame: From start of study drug administration up to EOS (up to approximately 15 months)

  19. Percentage of Participants With Major Clinical Events Related to Thrombotic Thrombocytopenic Purpura (TTP)

    Major clinical events related to TTP included Death, Stroke, MI and organ dysfunction not normalized within the 90-day observation period which consisted of chronic renal insufficiency, neurologic impairment and neurocognitive deficits.

    Time frame: From start of study drug administration up to EOS (up to approximately 15 months)

  20. Number of Participants With Major Clinical Events Related to PEX

    Major clinical events included clinically relevant bleeding (modified ITP score) or thrombosis at the site of line insertion, adverse reactions to plasma, including citrate reactions, allergic reactions, and transfusion-related acute lung injury (TRALI). Data is reported by summarizing the data for all parameters.

    Time frame: Up to 6 months

  21. Number of Participants With Anti-drug Antibody (ADA) Titer of Binding Relative to Baseline

    Time frame: Baseline and EOS (at approximately Month 15)

  22. Number of Participants With Inhibitory Antibodies Relative to Baseline

    Time frame: Baseline and EOS (at approximately Month 15)

  23. Percentage of Participants With at Least One Positive Identification of Antibodies to SHP655

    Percentages are based on the total number of participants per treatment group that have at least one ADA sample analyzed.

    Time frame: Up to 6 months

  24. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Specifically Product-Related TEAEs and Serious TEAEs

    AE=any untoward medical occurrence in a participants administered IP that does not necessarily have a causal relationship with the treatment. TEAE=an adverse event with an onset that occurs after receiving study drug. SAE=an AE with any untoward clinical manifestation of signs, symptoms or outcomes which results in death, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, important medical event, bronchospasm associated with anaphylaxis, reviewed and confirmed seroconversion for human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis E virus (HEV), or parvovirus B19 (B19V). A product related AE is any event emerging or manifesting at or after the initiation of treatment with an investigational product or medicinal product or any existing event that worsens.

    Time frame: From first dose of study drug until the EOS (up to approximately 15 months)

  25. Number of Participants With Clinically Relevant Changes in Vital Signs

    Vital signs were assessed based on blood pressure, pulse rate, respiratory rate and body temperature.

    Time frame: From first dose of study drug until the EOS (up to approximately 15 months)

  26. Number of Participants With Clinically Relevant Changes in Clinical Chemistry

    Clinical chemistry assessed alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, alkaline phosphatase, blood urea nitrogen, creatinine, and glucose.

    Time frame: From first dose of study drug until the EOS (up to approximately 15 months)

  27. Number of Participants With Clinically Relevant Changes in Hematology

    Hematology consisted of complete blood count and leukocytes with differential (basophils, eosinophils, lymphocytes, monocytes, neutrophils), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC) and platelet count.

    Time frame: From first dose of study drug until the EOS (up to approximately 15 months)

  28. Percentage of Participants Receiving Rescue Therapy

    Rescue therapy was defined as any product with a known interruption to the pharmacokinetic/ pharmacodynamic (PK/PD) relationship between ADAMTS-13 activity, von Willebrand factor (VWF) activity, and platelet count. If rescue therapy was initiated, the administration of IP (SHP655 or placebo) was suspended for the duration of the study. Number of participants experiencing occurrence of receiving rescue therapy was assessed.

    Time frame: From first dose of study drug until the EOS (up to approximately 15 months)

  29. Percentage of Participants Meeting Rescue Criteria

    Rescue therapy was defined as any product with a known interruption to the PK/PD relationship between ADAMTS-13 activity, VWF activity, and platelet count. If rescue therapy was initiated, the administration of IP (SHP655 or placebo) was suspended for the duration of the study. Number of participants experiencing occurrence in meeting rescue therapy criteria was assessed. Percentage of participants with rescue therapy initiated are based on laboratory criteria and adverse events.

    Time frame: From first dose of study drug until the EOS (up to approximately 15 months)

07

Results

Posted Dec 1, 2022

Participant flow

Participants took part in the study at 12 investigative sites in Canada, France, Great Britain, Spain and United States from 09 October 2019 to 05 August 2021.

Participant flow — Overall Study
MilestoneStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Started1099
Pharmacokinetic population1089
Completed968
Not completed131
Withdrew: Not meeting confirmatory inclusion criteria010
Withdrew: Lost to follow-up100
Withdrew: Reason not specified021

Outcome measures

PrimaryADAMTS-13 Activity Levels

ADAMTS-13 Activity Levels was assessed by fluorescence resonance energy transfer (FRETS) ADAMTS13 activity, with or without SHP655 Supplementation. Schedule A (Days 1, 2, 3, 4, 6, 8, 11, and every 3 days thereafter) or Schedule B (Days 1, 2, 3, 5, 7, 9, 12, and every 3 days thereafter). Data is reported for multiple timepoints as Within 15 minutes pre-PEX and post-PEX; Within 15 minutes, 0.5-3 hours, 4-6 hours post end of investigational product (IP) infusion 1; Within 15 minutes, 0.5-3 hours post end IP infusion 2; 30 minutes pre-IP infusion 2 of Schedule A and Schedule B (up to Day 11 or 12).

Time frame:
Up to Days 11 or 12
Reported as:
Mean · international units(IU)/ml
ADAMTS-13 Activity Levels
international units(IU)/mlStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
FRETS: Day 1: ≤15 min Pre-PEX0.1439 ± 0.19247NA ± NANA ± NA
FRETS: Day 1: ≤15 min Post-PEX0.5418 ± 0.183450.5011 ± 0.192360.3029 ± 0.29020
FRETS: Day 1: ≤15 min Post End of IP 10.4571 ± 0.191252.012 ± 0.828321.352 ± 0.93502
FRETS: Day 1: 0.5-3 Hour (hr) Post End of IP 10.4420 ± 0.208951.905 ± 0.833491.266 ± 0.98904
FRETS: Day 1: 4-6 hr Post End of IP 10.3197 ± 0.205451.163 ± 0.613430.7912 ± 0.69403
FRETS: Day 1: ≤30 min Pre-IP 20.2108 ± 0.197311.027 ± 0.559510.4949 ± 0.54891
FRETS: Day 1: ≤15 min Post End of IP 20.2267 ± 0.186601.022 ± 0.520601.545 ± 1.0854
FRETS: Day 1: 0.5-3 hr Post End of IP 20.2007 ± 0.200121.015 ± 0.564621.300 ± 1.1114
FRETS: Day 2: ≤15 min Pre-PEX0.1691 ± 0.159090.7650 ± 0.619290.9482 ± 0.99771
FRETS: Day 2: ≤15 min Post-PEX0.5801 ± 0.161070.7808 ± 0.365440.8426 ± 0.54317
FRETS: Day 2: ≤15 min Post End of IP 10.5433 ± 0.202671.965 ± 0.721221.977 ± 0.98427
FRETS: Day 2: 0.5-3 hr Post End of IP 10.5281 ± 0.248422.105 ± 1.06562.153 ± 1.3856
FRETS: Day 2: 4-6 hr Post End of IP 10.4170 ± 0.252021.622 ± 0.780461.411 ± 0.75100
FRETS: Day 2: ≤30 min Pre-IP 20.3117 ± 0.249341.309 ± 0.487871.044 ± 0.55923
FRETS: Day 2: ≤15 min Post End of IP 20.2998 ± 0.249601.283 ± 0.525501.960 ± 0.99952
FRETS: Day 2: 0.5-3 hr Post End of IP 20.2833 ± 0.239991.398 ± 0.475912.129 ± 1.4547
FRETS: Day 3: ≤15 min Pre-PEX0.2468 ± 0.236691.044 ± 0.541781.129 ± 1.0570
FRETS: Day 3: ≤15 min Post-PEX0.5342 ± 0.222510.7786 ± 0.164550.7020 ± 0.40432
FRETS: Day 3: ≤15 min Post End of IP 10.5215 ± 0.235222.210 ± 0.960571.911 ± 1.6633
FRETS: Day 3: 0.5-3 hr Post End of IP 10.4970 ± 0.239792.086 ± 0.855671.785 ± 1.1566
FRETS: Day 3: 4-6 hr Post End of IP 10.4670 ± 0.306461.680 ± 0.464571.271 ± 0.71567
FRETS: Day 3: ≤30 min Pre-IP 20.3424 ± 0.292751.196 ± 0.445501.041 ± 0.84152
FRETS: Day 3: ≤15 min Post End of IP 20.3514 ± 0.312641.263 ± 0.384681.478 ± 1.0343
FRETS: Day 3: 0.5-3 hr Post End of IP 20.3227 ± 0.281911.267 ± 0.435801.902 ± 1.4522
FRETS: Day 4 or 5: ≤15 min Pre-PEX0.2378 ± 0.305131.094 ± 0.677931.378 ± 1.1964
FRETS: Day 4 or 5: ≤15 min Post-PEX0.4554 ± 0.264050.8222 ± 0.210720.8725 ± 0.57834
FRETS: Day 4 or 5: ≤15 min Post End of IP 10.7599 ± 1.00622.257 ± 0.957911.679 ± 1.3803
FRETS: Day 4 or 5: 0.5-3 hr Post End of IP 10.6699 ± 0.768752.425 ± 1.48691.405 ± 1.0118
FRETS: Day 4 or 5: 4-6 hr Post End of IP 10.5663 ± 0.695811.741 ± 0.841711.214 ± 1.0280
FRETS: Day 4 or 5: ≤30 min Pre-IP 20.5045 ± 0.607301.290 ± 0.647451.255 ± 0.98796
FRETS: Day 4 or 5: ≤15 min Post End of IP 20.4596 ± 0.584981.288 ± 0.638012.306 ± 1.6006
FRETS: Day 4 or 5: 0.5-3 hr Post End of IP 20.4129 ± 0.495741.106 ± 0.590342.009 ± 1.4354
FRETS: Day 6 or 7: ≤15 min Pre-PEX0.1246 ± 0.24910NA ± NANA ± NA
FRETS: Day 6 or 7: ≤15 min Post-PEX0.2587 ± 0.301310.7311 ± 0.48855NA ± NA
FRETS: Day 6 or 7: ≤15 min Post End of IP 10.2150 ± 0.269241.481 ± 0.89773NA ± NA
FRETS: Day 6 or 7: 0.5-3 hr Post End of IP 10.2194 ± 0.249291.673 ± 1.0721NA ± NA
FRETS: Day 6 or 7: 4-6 hr Post End of IP 10.1443 ± 0.244851.467 ± 1.1232NA ± NA
FRETS: Day 6 or 7: ≤30 min Pre-IP 20.1272 ± 0.25440NA ± NANA ± NA
FRETS: Day 6 or 7: ≤15 Minutes Post End of IP 20.1422 ± 0.28435NA ± NANA ± NA
FRETS: Day 6 or 7: 0.5-3 hr Post End of IP 20.1336 ± 0.26710NA ± NANA ± NA
FRETS: Day 8 or 9: ≤15 min Pre-PEX—NA ± NA—
FRETS: Day 8 or 9: ≤15 min Post-PEX—NA ± NA—
FRETS: Day 8 or 9: ≤15 min Post End of IP 1—NA ± NA—
FRETS: Day 8 or 9: 0.5-3 hr Post End of IP 1—NA ± NA—
FRETS: Day 8 or 9: 4-6 hr Post End of IP 1—NA ± NA—
FRETS: Day 8 or 9: ≤30 Minutes Pre-IP 2—NA ± NA—
FRETS: Day 8 or 9: ≤15 min Post End of IP 2—NA ± NA—
FRETS: Day 8 or 9: 0.5-3 hr Post End of IP 2—NA ± NA—
FRETS: Day 11 or 12: ≤15 min Pre-PEX—NA ± NA—
FRETS: Day 11 or 12: ≤15 min Post-PEX—NA ± NA—
FRETS: Day 11 or 12: ≤30 min Pre-IP 2—NA ± NA—
FRETS: Day 11 or 12: ≤15 min Post End of IP 2—NA ± NA—
FRETS: Day 11 or 12: 0.5-3 hr Post End of IP 2—NA ± NA—
PrimaryPlatelet Count

The platelet counts are reported in units of 10\^9 per liter blood.

Time frame:
Baseline and end of study (EOS) (up to approximately 15 months)
Reported as:
Mean · 10^9 platelets/L
Platelet Count
10^9 platelets/LStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Baseline35.80 ± 32.07627.67 ± 17.57115.38 ± 7.463
EOS278.89 ± 79.592267.00 ± 86.906286.22 ± 109.264
PrimaryLactate Dehydrogenase (LDH) Levels

The lactate dehydrogenase levels are reported.

Time frame:
Baseline and EOS (up to approximately 15 months)
Reported as:
Mean · international units (IU)/L
Lactate Dehydrogenase (LDH) Levels
international units (IU)/LStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Baseline634.6 ± 378.37616.3 ± 478.14787.8 ± 188.39
EOS197.3 ± 42.00208.8 ± 75.20220.4 ± 69.93
SecondaryDose(s) of SHP655 Needed to Achieve and Maintain Adequate Plasma Levels of rADAMTS-13

Dose(s) of SHP655 needed to achieve and maintain adequate plasma levels of rADAMTS-13 in order to support induction of remission and to reduce the number of PEX procedures needed for the treatment of acute aTTP episodes was assessed.

Time frame:
From start of study drug administration up to 13 weeks (following remission up to 6 months)

No measurements were reported for this outcome.

SecondaryPK/PD Temporal Relationship of Safety and Efficacy Parameter as a Function of ADAMTS-13 Activity

Parameters included platelet and LDH counts.

Time frame:
Up to 6 months

No measurements were reported for this outcome.

SecondaryNumber of Participants With ADAMTS-13 Binding Antibodies Per Titer

Antibody titer indicates the level of the antibodies in a blood sample, defined as the greatest dilution (or lowest concentration) of the blood sample at which an antibody assay (such as ELISA for e.g.), still produces a detectable positive result. Data is presented per titer for ADA positive participants only.

Time frame:
Baseline and EOS (up to approximately 15 months)
Reported as:
Count of participants · Participants
Number of Participants With ADAMTS-13 Binding Antibodies Per Titer
ParticipantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Baseline- 1:20231
Baseline- 1:40322
Baseline- 1:80201
Baseline- 1:160012
Baseline- 1:320020
Baseline- 1:640001
Baseline- 1:1280001
EOS- 1:20010
EOS- 1:40201
EOS- 1:80102
EOS- 1:2560010
EOS- 1:5120001
EOS- 1:81920001
SecondaryInhibitory Autoantibodies (Nab) Titer Levels

NAb titers were summarized (median, minimum and maximum) at baseline and EOS per treatment arms, in those subjects with NAb positive results (NAb positive is defined as titer value \>=0.6 BU/mL).

Time frame:
Baseline and EOS (up to approximately 15 months)
Reported as:
Median · BU/mL
Inhibitory Autoantibodies (Nab) Titer Levels
BU/mLStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Baseline1.25 (0.6 to 3.4)1.25 (1.0 to 1.8)1.80 (0.6 to 4.0)
EOS0.60 (0.6 to 0.6)0.70 (0.7 to 1.7)4.00 (4.0 to 4.0)
SecondaryADAMTS-13 Activity Levels in Participants Receiving Additional SHP655 for up to 30 Days After Resolution by Using FRETS

ADAMTS-13 activity levels in participants receiving additional SHP655 for up to 30 days after the resolution of the thrombotic thrombocytopenic purpura (TTP) episode were assessed. Resolution was defined as a normal platelet count and LDH \<2 ULN for at least 48 hours following initial normalization of platelet count (acute episode period).

Time frame:
At Days 3, 7, 10, 21, 28, 42, 56 and 84
Reported as:
Mean · IU/mL
ADAMTS-13 Activity Levels in Participants Receiving Additional SHP655 for up to 30 Days After Resolution by Using FRETS
IU/mLStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Day 30.4602 ± 0.14328NA ± NA0.1171 ± 0.28688
Day 70.3037 ± 0.269210.3180 ± 0.34714NA ± NA
Day 100.9021 ± 0.205200.5518 ± 0.339620.4904 ± 0.46441
Day 210.8102 ± 0.527730.6264 ± 0.609710.5320 ± 0.51432
Day 280.8830 ± 0.515160.8931 ± 0.413230.8632 ± 0.62848
Day 420.9968 ± 0.367450.8842 ± 0.397841.055 ± 0.36080
Day 561.088 ± 0.255240.9923 ± 0.336631.092 ± 0.19961
Day 840.9708 ± 0.438311.021 ± 0.657150.6051 ± 0.48113
SecondaryRelationship Between ADAMTS-13 Activity and End-organ Disease Status

End-organ disease status were evaluated for renal, cardiac and neurological diseases.

Time frame:
Up to 6 months

No measurements were reported for this outcome.

SecondaryPredose Concentration (Cpre) to Maximum Plasma Concentration (Cmax) Ratio
Time frame:
Pre-PEX and post-PEX at multiple timepoints at Days 1, 2, 3, 4 or 5, 6 or 7, 8 or 9, and 11 or 12
Reported as:
Mean · ratio
Predose Concentration (Cpre) to Maximum Plasma Concentration (Cmax) Ratio
ratioStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
FRETS: Day 12.744 ± 3.3837NA ± NANA ± NA
FRETS: Day 22.587 ± 0.921763.534 ± 2.43733.675 ± 2.3380
FRETS: Day 31.669 ± 0.340452.134 ± 0.453922.268 ± 1.0679
FRETS: Day 4 or 5NA ± NA2.543 ± 0.595761.972 ± 0.91248
FRETS: Day 6 or 7NA ± NANA ± NANA ± NA
FRETS: Day 8 or 9—NA ± NA—
SecondaryAUC Overall: Area Under the Plasma Concentration Time Curve ADAMTS13 Activity by Using FRETS
Time frame:
Within 15 min pre-PEX and at multiple timepoints Post PEX at Days 1, 2, 3, 4 or 5 and 6 or 7
Reported as:
Mean · h*IU/mL
AUC Overall: Area Under the Plasma Concentration Time Curve ADAMTS13 Activity by Using FRETS
h*IU/mLStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Day 13.563 ± 2.555119.87 ± 9.115012.80 ± 8.4633
Day 24.461 ± 3.948024.16 ± 9.032321.97 ± 11.135
Day 35.590 ± 4.723222.75 ± 5.654923.49 ± 9.2589
Day 4 or 59.507 ± 11.59224.10 ± 11.35722.05 ± 14.192
Day 6 or 7NA ± NANA ± NANA ± NA
SecondarySystemic and Antibody Induced Clearance
Time frame:
15 minutes pre-PEX,15 minutes post-PEX,15 minutes, 0.5-3 hours, 4-6 hours post end of IP infusion 1,30 minutes pre-IP infusion 2,15 minutes, 0.5-3 hours post-IP infusion 2 of Schedule A or Schedule B (up to 6 months)

No measurements were reported for this outcome.

SecondaryCmax: Maximum ADAMTS-13 Activity Between PEX or SHP655 Infusions by Using FRETS
Time frame:
Pre-PEX and post-PEX at multiple timepoints at Days 1, 2, 3, 4 or 5, 6 or 7, 8 or 9, and 11 or 12
Reported as:
Mean · IU/mL
Cmax: Maximum ADAMTS-13 Activity Between PEX or SHP655 Infusions by Using FRETS
IU/mLStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Day 10.4157 ± 0.170752.011 ± 0.790361.653 ± 1.0655
Day 20.4951 ± 0.271782.153 ± 1.14042.458 ± 1.4369
Day 30.4307 ± 0.284202.228 ± 0.939682.222 ± 1.5080
Day 4 or 50.6438 ± 0.977672.633 ± 1.49552.377 ± 1.5934
Day 6 or 70.1362 ± 0.0952831.625 ± 1.0126NA ± NA
Day 8 or 9—NA ± NA—
SecondaryTrough Levels of ADAMTS-13 Prior PEX ADAMTS13 Activity by Using FRETS
Time frame:
Within 15 min pre-PEX and at multiple timepoints Post PEX at Days 2, 3, 4 or 5 and 6 or 7
Reported as:
Mean · IU/mL
Trough Levels of ADAMTS-13 Prior PEX ADAMTS13 Activity by Using FRETS
IU/mLStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Day 20.1667 ± 0.173080.8493 ± 0.621390.9274 ± 0.93426
Day 30.2579 ± 0.268361.110 ± 0.526121.174 ± 0.93910
Day 4 or 50.3138 ± 0.384161.180 ± 0.659051.378 ± 1.1976
Day 6 or 70.1660 ± 0.287521.070 ± 0.98879NA ± NA
SecondaryPercentage of Participants With ADAMTS-13 Activity Trough Levels >10%
Time frame:
Pre-dose at Days 2, 3 4 or 5, 6 or 7, 8 or 9, and 11 or 12
Reported as:
Number · percentage of participants
Percentage of Participants With ADAMTS-13 Activity Trough Levels >10%
percentage of participantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Day 257.1100.077.8
Day 357.1100.085.7
Day 4 or 550.0100.0100.0
Day 6 or 733.366.750.0
Day 8 or 9—100.0—
Day 11 or 12—100.0—
SecondaryNumber of Participants Who Achieved Remission Following Normalization of Platelet Count

Remission was defined as the time taken to achieve platelet count ≥150,000/μL, which was confirmed by a second normal platelet count ≥150,000/μL and LDH \<2 ULN 48 hours following initial normalization.

Time frame:
From the start of study drug administration up to 6 months post remission
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Remission Following Normalization of Platelet Count
ParticipantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Number of Participants Who Achieved Remission Following Normalization of Platelet Count988
SecondaryPercentage of Participants Achieving Remission

Remission was defined as a normal platelet count and LDH \<2 upper limit of normal (ULN) for at least 48 hours following initial normalization of platelet count (acute episode period). Normalization of platelet count was defined ≥150,000/μL, which was confirmed by a second normal platelet count ≥150,000/μL and LDH \<2 ULN.

Time frame:
From the start of study drug administration up to 6 months post remission
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission
percentage of participantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Percentage of Participants Achieving Remission100.0 (69.15 to 100.00)100.0 (63.06 to 100.00)88.9 (51.75 to 99.72)
SecondaryTime to First Exacerbation

Exacerbation was defined as recurrent thrombocytopenia following a response and requiring a reinitiation of daily plasma exchange treatment after ≥1 day but ≤30 days of no plasma exchange treatment. Data is reported based on Kaplan-Meier estimates. Data was reported for time to first exacerbation in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).

Time frame:
From start of study drug administration up to EOS (up to approximately 15 months)
Reported as:
Median · days
Time to First Exacerbation
daysStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
From Study Start up to 11 MonthsNA (2.00 to NA)NA (NA to NA)8.0 (5.00 to NA)
From 11 Months up to EOS (up to approximately 15 months)NA (4.00 to NA)NA (NA to NA)NA (6.00 to NA)
SecondaryTime to Relapse

Relapse was determined by platelet count or the occurrence after remission of a major clinical event (e.g., Myocardial Infraction (MI), stroke, death) deemed by the investigator to be related to aTTP. Data was reported for time to relapse in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).

Time frame:
From start of study drug administration up to EOS (up to approximately 15 months)
Reported as:
Median · days
Time to Relapse
daysStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
From Study Start up to 11 MonthsNA (NA to NA)NA (NA to NA)NA (NA to NA)
From 11 Months up to EOS (up to approximately 15 months)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With Exacerbation

Exacerbation was determined by platelet count or the occurrence after remission of a major clinical event (e.g., myocardial infarction (MI), stroke, death) deemed by the investigator to be related to aTTP. Data was reported for percentage of participants with exacerbation in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).

Time frame:
From start of study drug administration up to EOS (up to approximately 15 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Exacerbation
percentage of participantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
From Study Start up to 11 Months50.0 (6.76 to 93.24)0.0 (0.00 to 60.24)60.0 (14.66 to 94.73)
From 11 Months up to EOS (up to approximately 15 months)33.3 (4.33 to 77.72)0.0 (0.00 to 60.24)33.3 (0.84 to 90.57)
SecondaryPercentage of Participants With Relapse

Relapse was determined by platelet count or the occurrence after remission of a major clinical event (e.g., Myocardial Infraction (MI), stroke, death) deemed by the investigator to be related to aTTP. Data was reported for percentage of participants with exacerbation in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).

Time frame:
From start of study drug administration up to EOS (up to approximately 15 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Relapse
percentage of participantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
From Study Start up to 11 Months0.0 (0.0 to 60.24)0.0 (0.0 to 60.24)0.0 (0.0 to 52.18)
From 11 Months up to EOS (up to approximately 15 months)0.0 (0.0 to 45.93)0.0 (0.0 to 60.24)0.0 (0.0 to 70.76)
SecondaryPercentage of Participants With Major Clinical Events Related to Thrombotic Thrombocytopenic Purpura (TTP)

Major clinical events related to TTP included Death, Stroke, MI and organ dysfunction not normalized within the 90-day observation period which consisted of chronic renal insufficiency, neurologic impairment and neurocognitive deficits.

Time frame:
From start of study drug administration up to EOS (up to approximately 15 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Major Clinical Events Related to Thrombotic Thrombocytopenic Purpura (TTP)
percentage of participantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Renal Insufficiency90.0100.088.9
Neurologic Deficits60.0100.077.8
Brain Injury50.062.566.7
Death, Stroke and MI000
SecondaryNumber of Participants With Major Clinical Events Related to PEX

Major clinical events included clinically relevant bleeding (modified ITP score) or thrombosis at the site of line insertion, adverse reactions to plasma, including citrate reactions, allergic reactions, and transfusion-related acute lung injury (TRALI). Data is reported by summarizing the data for all parameters.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Number of Participants With Major Clinical Events Related to PEX
ParticipantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Number of Participants With Major Clinical Events Related to PEX611
SecondaryNumber of Participants With Anti-drug Antibody (ADA) Titer of Binding Relative to Baseline
Time frame:
Baseline and EOS (at approximately Month 15)
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibody (ADA) Titer of Binding Relative to Baseline
ParticipantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Baseline788
EOS at Month 15325
SecondaryNumber of Participants With Inhibitory Antibodies Relative to Baseline
Time frame:
Baseline and EOS (at approximately Month 15)
Reported as:
Count of participants · Participants
Number of Participants With Inhibitory Antibodies Relative to Baseline
ParticipantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Baseline6 (0.6 to 3.4)4 (1.0 to 1.8)7 (0.6 to 4.0)
EOS at Month 153 (0.6 to 0.6)3 (0.7 to 1.7)2 (4.0 to 4.0)
SecondaryPercentage of Participants With at Least One Positive Identification of Antibodies to SHP655

Percentages are based on the total number of participants per treatment group that have at least one ADA sample analyzed.

Time frame:
Up to 6 months
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Positive Identification of Antibodies to SHP655
percentage of participantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
ADA Positive: up to 3 Months80.062.588.9
ADA Positive: up to 6 Months20.075.033.3
Nab Positive: up to 3 Months40.037.533.3
Nab Positive: up to 6 Months30.037.522.2
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Specifically Product-Related TEAEs and Serious TEAEs

AE=any untoward medical occurrence in a participants administered IP that does not necessarily have a causal relationship with the treatment. TEAE=an adverse event with an onset that occurs after receiving study drug. SAE=an AE with any untoward clinical manifestation of signs, symptoms or outcomes which results in death, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, important medical event, bronchospasm associated with anaphylaxis, reviewed and confirmed seroconversion for human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis E virus (HEV), or parvovirus B19 (B19V). A product related AE is any event emerging or manifesting at or after the initiation of treatment with an investigational product or medicinal product or any existing event that worsens.

Time frame:
From first dose of study drug until the EOS (up to approximately 15 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Specifically Product-Related TEAEs and Serious TEAEs
ParticipantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Any TEAEs1098
Specifically Product-Related TEAEs010
Serious TEAEs413
SecondaryNumber of Participants With Clinically Relevant Changes in Vital Signs

Vital signs were assessed based on blood pressure, pulse rate, respiratory rate and body temperature.

Time frame:
From first dose of study drug until the EOS (up to approximately 15 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Relevant Changes in Vital Signs
ParticipantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Number of Participants With Clinically Relevant Changes in Vital Signs000
SecondaryNumber of Participants With Clinically Relevant Changes in Clinical Chemistry

Clinical chemistry assessed alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, alkaline phosphatase, blood urea nitrogen, creatinine, and glucose.

Time frame:
From first dose of study drug until the EOS (up to approximately 15 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Relevant Changes in Clinical Chemistry
ParticipantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Number of Participants With Clinically Relevant Changes in Clinical Chemistry000
SecondaryNumber of Participants With Clinically Relevant Changes in Hematology

Hematology consisted of complete blood count and leukocytes with differential (basophils, eosinophils, lymphocytes, monocytes, neutrophils), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC) and platelet count.

Time frame:
From first dose of study drug until the EOS (up to approximately 15 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Relevant Changes in Hematology
ParticipantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Number of Participants With Clinically Relevant Changes in Hematology000
SecondaryPercentage of Participants Receiving Rescue Therapy

Rescue therapy was defined as any product with a known interruption to the pharmacokinetic/ pharmacodynamic (PK/PD) relationship between ADAMTS-13 activity, von Willebrand factor (VWF) activity, and platelet count. If rescue therapy was initiated, the administration of IP (SHP655 or placebo) was suspended for the duration of the study. Number of participants experiencing occurrence of receiving rescue therapy was assessed.

Time frame:
From first dose of study drug until the EOS (up to approximately 15 months)
Reported as:
Number · percentage of participants
Percentage of Participants Receiving Rescue Therapy
percentage of participantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Percentage of Participants Receiving Rescue Therapy20.0022.2
SecondaryPercentage of Participants Meeting Rescue Criteria

Rescue therapy was defined as any product with a known interruption to the PK/PD relationship between ADAMTS-13 activity, VWF activity, and platelet count. If rescue therapy was initiated, the administration of IP (SHP655 or placebo) was suspended for the duration of the study. Number of participants experiencing occurrence in meeting rescue therapy criteria was assessed. Percentage of participants with rescue therapy initiated are based on laboratory criteria and adverse events.

Time frame:
From first dose of study drug until the EOS (up to approximately 15 months)
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Rescue Criteria
percentage of participantsStandard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655
Percentage of Participants Meeting Rescue Criteria10.00.011.1

Adverse events

Collected over From start of study drug administration up to end of the study (up to approximately 15 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Post PEX + Placebo 12H Post PEX0/10 (0%)4/10 (40%)10/10 (100%)
SHP655 40 IU/kg Post PEX + Placebo 12H Post PEX0/9 (0%)1/9 (11.1%)9/9 (100%)
SHP655 40 IU/kg Post PEX + SHP655 40 IU/kg 12H Post PEX0/9 (0%)3/9 (33.3%)6/9 (66.7%)
Most frequent serious events
Most frequent serious events
EventPlacebo Post PEX + Placebo 12H Post PEXSHP655 40 IU/kg Post PEX + Placebo 12H Post PEXSHP655 40 IU/kg Post PEX + SHP655 40 IU/kg 12H Post PEX
Thrombotic thrombocytopenic purpuraBlood and lymphatic system disorders3/100/92/9
CholecystitisHepatobiliary disorders0/101/90/9
PneumoniaInfections and infestations0/101/90/9
ThrombocytopeniaBlood and lymphatic system disorders0/100/91/9
CholelithiasisHepatobiliary disorders1/100/90/9
Drug hypersensitivityImmune system disorders1/100/90/9
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/100/90/9
Most frequent other events
Showing 10 of 113
Most frequent other events
EventPlacebo Post PEX + Placebo 12H Post PEXSHP655 40 IU/kg Post PEX + Placebo 12H Post PEXSHP655 40 IU/kg Post PEX + SHP655 40 IU/kg 12H Post PEX
ConstipationGastrointestinal disorders1/103/91/9
Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders3/100/90/9
NauseaGastrointestinal disorders3/100/90/9
PruritusSkin and subcutaneous tissue disorders3/101/90/9
PyrexiaGeneral disorders3/101/91/9
Alanine aminotransferase increasedInvestigations1/102/91/9
DiarrhoeaGastrointestinal disorders1/102/90/9
Heart rate increasedInvestigations0/102/90/9
HypokalaemiaMetabolism and nutrition disorders0/102/90/9
ParaesthesiaNervous system disorders0/102/90/9

Baseline characteristics

Safety Analysis Set (SAS) included all participants randomized, who received any dose of investigational product.

Age, Continuous
Age, Continuous(years)Standard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655Total
Mean41.2 ± 10.8051.9 ± 14.8148.4 ± 14.9347.0 ± 13.82
Sex: Female, Male
Sex: Female, Male(Participants)Standard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655Total
Female86519
Male2349
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Standard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655Total
Hispanic or Latino0101
Not Hispanic or Latino108927
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Standard of Care (SoC) + PlaceboSoC + SHP655 + PlaceboSoC + SHP655Total
Race — American Indian or Alaska Native0000
Race — Asian0101
Race — Black or African American4127
Race — White65617
Race — Native Hawaiian or Other Pacific Islander0000
Race — Other0202
Race — Missing0011
08

Study locations

24 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106-4948, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • London Health Sciences Centre (LHSC) - University Hospital
    London, Ontario N6A 5A5, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • CHU de Reims - Hôpital Maison Blanche
    Reims, Marne 51092, France
  • Hopital Conception
    Marseille, 13005, France
  • Chu Saint-Antoine
    Paris, 75012, France
  • CHU de Rouen
    Seine Maritime, 76031, France
  • Hamatologie, Onkologie, Hämostaseologie
    Frankfurt, D-60590, Germany
  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Rome, 137, Italy
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
  • Hospital Dr. Peset
    Valencia, 46017, Spain
  • Hospital Universitari i Politècnic la Fe
    Valencia, 46026, Spain
  • University Hospital of Wales
    Cardiff, West Glamorgan CF14 4XW, United Kingdom
  • Royal Liverpool University Hospital
    Liverpool, L7 8XP, United Kingdom
  • 1st Floor, UCLH-Haematology
    London, WC1E 6HX, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Aug 2021, 21 months.

Results were first posted in Dec 2022, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2019
First posted
Apr 19, 2019
StartActual
Oct 9, 2019
Primary completionActual
Aug 5, 2021
CompletionActual
Aug 5, 2021
Results first posted
Dec 1, 2022
Last update
Dec 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03922308
Lead sponsor
Shire
Collaborators
Takeda Development Center Americas, Inc.
Responsible party
Sponsor
First posted
Apr 19, 2019
Start date
Oct 9, 2019
Primary completion
Aug 5, 2021
Completion
Aug 5, 2021
Results posted
Dec 1, 2022
Last update
Dec 1, 2022

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apadamtase alfa

Start the discussion